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ABSTRACT
(57)
A method for treating brain-related chronic pain disorders in
human Subjects includes assessing the brain function of a
Subject suffering from chronic pain, diagnosing a chronic
pain-related abnormal brain condition, and mitigating the
abnormal brain activity by applying an electrical stimulation
signal to tissues corresponding to at least one area of abnor
mal brain activity.
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BRAIN-RELATED CHRONIC PAIN
DISORDER TREATMENT METHOD AND
APPARATUS
CROSS-REFERENCES TO RELATED
APPLICATIONS

0001. This application claims the benefit and is a continu
ation of U.S. patent application Ser. No. 12/865,286 filed on
Jul. 29, 2010; which is a continuation of U.S. patent applica
tion Ser. No. 12/187,375 filed on Aug. 6, 2008; which is a
continuation-in-part of U.S. patent application Ser. No.
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SUMMARY OF THE INVENTION

0006. A method for treating a brain-related chronic pain
disorder in a human Subject is provided. According to this
method one can treat a brain-related chronic pain disorder in
a human Subject by assessing the brain function of a subject
Suffering from chronic pain, diagnosing a chronic pain-re
lated abnormal brain condition, and mitigating the abnormal
brain activity by applying an electrical stimulation signal to
tissues corresponding to the at least one area of abnormal
brain activity.

1 1/490,255 filed on Jul. 21, 2006, now U.S. Pat. No. 7,715,

BRIEF DESCRIPTION OF THE DRAWINGS

910 issued on May 11, 2010; which is a continuation of U.S.
patent application Ser. No. 10/357,503 filed on Feb. 4, 2003
which in now abandoned; and claims priority to PCT/

0007. These and other features and advantages of the
invention will become apparent to those skilled in the art in
connection with the following detailed description, drawings,
photographs, and appendices, in which:
0008 FIG. 1A is a flow chart depicting a method per
formed according to the invention;
0009 FIG. 1B is a continuation of the flow chart of FIG.

US2008/087451 filed on Dec. 18, 2008: PCT/US2008/

072395 filed Aug. 6, 2008; and PCT/US2008/072389 filedon
Aug. 6, 2008; and in turn claims the benefit to U.S. Provi
sional Application Ser. No. 61/032,241 filedon Feb. 28, 2008:
U.S. Provisional Application Ser. No. 61/024,641 filed on
Jan. 30, 2008; U.S. Provisional Application Ser. No. 61/014,
917 filed on Dec. 19, 2007; U.S. Provisional Application Ser.
No. 60/963.486 filed on Aug. 6, 2007 and U.S. Provisional
Application Ser. No. 60/353,234 filed on Feb. 4, 2002; all of
which are incorporated herein by reference in their entireties.

fio

FIG. 1C is a continuation of the flow chart of FIG.

fill FIG. 1D is a continuation of the flow chart of FIG.
Foia

FIG. 1E is a continuation of the flow chart of FIG.

TECHNICAL FIELD

Fis FIG. 2 is a schematic diagram showing an apparatus

0002 This invention relates generally to a method and
apparatus for treating brain-related chronic pain disorders in
human Subjects.

for treating a brain-related chronic pain disorder according to

BACKGROUND OF THE INVENTION

0003. Few methods are known in the prior art for treating
brain-related chronic pain disorders such as fibromyalgia.
U.S. Pat. No. 7,146,205 issued 5 Dec. 2006 to Holman, dis

closes a fibromyalgia treatment method including the use of
inhibitors of sympathetic nervous system activities. U.S. Pat.
No. 5,990,162, issued 23 Nov. 1999 to Scharf, discloses a

fibromyalgia treatment method that involves the use of
butyrate derivatives. U.S. Pat. No. 5,378,686, issued 3 Jan.
1995 to Bennett, discloses a fibromyalgia treatment involving
the use of Supplemental growth hormone. In each of these
documents the inventors teach methods that likely address
central nervous system and neurotransmitter outcomes that
result from the fundamental role of brain function in the

pathology of fibromyalgia. However, the methods disclosed
in these patents are unable to treat the fundamental brain
function abnormality related to fibromyalgia that causes
chronic pain.
0004. In addition, United States Patent Application Publi
cation No. 20070191905 published 16 Aug. 2007; Nos.
20070179563 and 20070179564 published 2 Aug. 2007, No.
20070156182 published 5 Jul. 2007, No. 20070106339 pub
lished 10 May 2007, and No. 20070106342 published 10 May
2007, disclose the use of electrical stimulation to treat

hypotension, vision disorders, dysphagia, and pain, respec
tively. However, none of the methods disclosed in these pub
lications are able to treat a brain function abnormality that is
at least partially responsible for causing chronic pain.
0005 What is needed is a method and apparatus for treat
ing brain-related chronic pain disorders in human Subjects
that can treat a fundamental brain function abnormality asso
ciated with chronic pain.

the invention;

0014 FIG. 3 is a schematic diagram showing a signal
generating circuit of the apparatus of FIG. 2;
0015 FIG. 4 is a schematic diagram showing an embodi
ment of an apparatus for treating a brain-related chronic pain
disorder according to the invention and showing atherapy cap
of the apparatus and a subjects head cut-away to reveal
electrical stimulation signal paths relative to target areas of
the subject’s brain tissue:
0016 FIG. 5 is a schematic diagram showing an embodi
ment of an apparatus for treating a brain-related chronic pain
disorder according to the invention and showing atherapy cap
of the apparatus cut-away to reveal an RFID chip carried by
the cap; and
0017 FIG. 6 is a schematic diagram showing an embodi
ment of an apparatus for treating a brain-related chronic pain
disorder according to the invention and showing atherapy cap
of the apparatus cut-away to reveal a programmable memory
circuit carried by the cap.
DETAILED DESCRIPTION OF INVENTION

EMBODIMENT(S)
0018. A method is provided for treating a brain-related
chronic pain disorder. The method includes assessing the
brain function of a Subject Suffering from chronic pain, diag
nosing a chronic pain-related abnormal brain condition,
locating at least one area of abnormalbrainactivity associated
with the abnormal brain condition and mitigating the abnor
mal brain activity by applying a neuromodulation signal to
tissues corresponding to the at least one area of abnormal
brain activity. Alternatively, the neuromodulation signal com
prises waveforms designed to minimize tissue impedance
while effecting noninvasive neuromodulation. Treatment
effect is realized when abnormal brain function has been

improved or corrected.
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0019. A physical assessment may first be performed of a
human Subject presenting with a complaint of symptoms
characteristic of a chronic pain condition Such as fibromyal
gia. The physical assessment may include, among other
things, a determination of chronic widespread pain, sleep
difficulty, fatigue, morning stiffness of the muscles and joints,
cognitive difficulty, and other symptoms associated with the
condition. The physical assessment may also include tests
performed to exclude various non-fibromyalgia conditions as
the cause of the symptoms. Such further testing may include
palpation of 18 tender points in the manner prescribed by the
American College of Rheumatology, with Such palpation
being performed to determine whether the subject has an
abnormal sensitivity to pain.
0020. In the absence of an alternate, non-fibromyalgia
diagnosis, an electroencephalogram (EEG) test may be per
formed in addition to the physical assessment, whereby the
EEG test is performed utilizing methods and apparatus well
known in the art. Specifically, the Subject may be made com
fortable by, for example, being seated, or reclined. Prepara
tion of the scalp in accordance with commonly followed
procedures for performing a clinical EEG may be done by a
person of sufficient competence. EEG electrodes may then be
adapted to be worn on the Scalp, preferably in Scalp locations
identified as the “International 10-20 standard sites, using
common methods of affixing the electrodes Such that they rest
on or otherwise contact tissues.

0021 While any number of electrodes may be used, a
preferred number is either 19 or 24, in accordance with the
number of electrode sites used to construct various indepen
dent databases utilized to represent the EEG of a healthy
normal population, and to facilitate quantitative assessment
(qEEG) of the subjects EEG. Methods involving qEEG
include a number of mathematical analyses utilized to make
statistical comparisons between the Subject’s qEEG and a
database of qEEGs of either healthy normal individuals’ brain
functions or the brain functions of individuals suffering from
chronic pain related brain function conditions.
0022 Records of the subject's EEG from each electrode
site may then be acquired under the conditions of both their
eyes being closed and their eyes being open, with each con
dition producing a separate data record. In other words, an
“eyes open' EEG record may be obtained, which includes
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left lateral epicondyle of the arms approximately two centi
meters distal of the elbows, and tender points adjacent the
right and left costochondral junctions of the second rib.
0024. The TPP test may be executed by acquiring an EEG
record (“TPP” EEG record) including EEG data obtained
from the electrode sites for a first tender point by first com
mencing the acquisition of EEG data and then, a short period
of time later, commencing palpation of the first tender point.
Preferably, the period of time between the commencement of
data acquisition and the commencement of palpation of the
first tender point may be between one and 300 seconds. Pal
pation of the first tender point may be accomplished by press
ing on the tender point preferably pressing or palpating
through the use of an algometer, and preferably at a rate of
approximately one kilogram per centimeter squared per sec
ond, until the Subject reports a painful sensation or until
reaching a pressure of 4 kilograms per centimeter squared—
whichever occurs first. Preferably, palpation pressure may be
removed as soon as the Subject reports a painful sensation. A
record is made of the amount of the pressure being applied at
the moment the Subject reports a painful sensation.
(0025. Further according to the TPP test method, the
recording of the “eyes closed EEG may continue for a period
of time after release of palpation pressure, preferably between
1 and 300 seconds, and most preferably, for at least 60 sec
onds. Following this period, a second and Subsequent tender
point may be serially palpated with an algometer in the same
manner as described for the first, with “TPP” EEG records

being recorded for each by recording the “eyes closed EEG
for each site in the manner described with regard to obtaining
the “TPP” EEG record for the first site. This process may be
repeated for each chosen tender point. Accordingly, the
resulting EEG data record includes the “TPP” EEG records
acquired for each chosen tender point.
(0026. The “TPP” EEG records may be acquired for a
period of time that is sufficient to extract from each “TPP
EEG record a minimum of 60 seconds of “clean EEG data,
that is, data free of extraneous electrical noise Such as that

ject’s eyes are open and an “eyes closed EEG record may be

from electromyographic movement. Preferably, all EEG
records (“eyes open EEG records, “eyes closed EEG
records, and “TPP” EEG records) may be individually edited
to provide from each EEG record a minimum of 60 seconds of
clean EEG. Preferably, the clean data is obtained to present a
high degree of statistical consistency. Such measures as
“Split-Half reliability, which is the ratio of variance between

obtained, which includes EEG data obtained from each elec

the even and odd seconds of the time series of selected clean

trode site while the subject’s eyes are closed. Preferably, a
minimum of five minutes of EEG data may be obtained from
each electrode site for each "eyes open EEG record and a
minimum of five minutes of EEG data may be obtained from
each electrode site for each "eyes closed EEG record to
assure that enough EEG data is recorded to produce statisti
cally significant samples from each electrode site, both with
the subject’s eyes open and with the subject’s eyes closed.

EEG; and “Test Re-test” reliability, which is the ratio of

EEG data obtained from each electrode site while the sub

This is further described below.

0023 Preferably, an additional test may be performed in
which at least one additional EEG record is made that
includes EEG data obtained at each electrode site while the

subject’s eyes are closed. In this test, henceforth referred to as
a “tender point palpation (TPP) test”, a number of tender
points on the Subject’s body, preferably ranging between one
and 18, are identified and serially palpated with an algometer.
Preferably, four tender points may be chosen, and, preferably,
those four points include tender points adjacent the right and

variance between the first half and the second half of the

selected clean EEG segments may be used. Preferably, clean
EEG data is obtained such that measures of these ratios are a

minimum of 0.95 and 0.90 respectively, which is consistent
with levels of reliability commonly published in EEG litera
ture.

(0027. With regard to the TPP test method, clean data
includes only that EEG data acquired after palpation of a
tender point, and does not include any EEG data acquired
during the palpation of a tender point. In addition, to assess
the stability of a “TPP” EEG record, EEG data acquired
before palpation of a tenderpoint may be removed, edited and
statistically compared to like data in the “eyes closed EEG
record obtained from the “eyes closed EEG test. Stability of
the “eyes closed” and “TPP” EEG records is indicated by a
finding that there is no statistically significant difference
between the “eyes closed EEG record and the pre-palpation
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portion of the “TPP EEG record. A contrary finding indi
cates instability and a need to repeat the EEG tests.
0028. Further to the method, and in the preferred embodi
ment, clean “eyes open”, “eyes closed”, and “PPT EEG
records may be then mathematically analyzed for various
time domain and frequency domain parameters of their
respective electrical signals. These analyses may include, but
are not limited to Voltage analysis, current analysis, Voltage
and current analysis, frequency spectrum analysis using Fast
Fourier transform analysis, frequency spectrum analysis
using a wavelet analysis method, frequency spectrum analy
sis using absolute power analysis method, frequency spec
trum analysis using relative power analysis method, fre
quency spectrum analysis using phase analysis method,
frequency spectrum analysis using coherence analysis
method, frequency spectrum analysis using amplitude sym

cant'. However, inclinical application statistically significant
differences may be declared with p-values at the 0.1 level or
less.

0031. Further EEG abnormalities consistent with those
observed in a sample population offibromyalgia patients, and
drawn particularly to the TPP test method, may include but
are not limited to a finding of (1) a statistically significant
increase in EEG absolute power, particularly in the alpha and
beta segments, in the parietal, occipital, and temporal areas of
the brain as compared to the “eyes closed EEG record ("eyes
closed EEG findings without tender point palpation) for the
same Subject; or (2) a statistically significant increase in
coherence in the alpha or beta segment of EEG. The following
are the results of tests of the predictive value of TPP sensitiv
ity analysis, obtained when TPP testing was utilized on 19
fibromyalgia patients and compared to TPP testing done on
nine healthy normal controls:
Positive

(2t Criterion for Making a Diagnosis of Fibromyalgia

(2nsitivity (2)ecificity (2)ictive Value

(2)crease in alpha EEG of at least 20% in at least one

63%

89%

92%

(2ncrease in alpha EEG of at least 20% in at least one

84%

78%

89%

(2)otal regions of increase in alpha EEG of at least 20%

74%

100%

100%

84%

88%

94%

90%

100%

100%

occipital or parietal site
temporal site

are greater than two

(2EEG coherence increases by at least 20% in at least
30 out of 171 possible site combinations

(2)ast two (2) positive findings occur in any of the four
previous tests
*Based on comparison of TPPEEG data against eyes closed EEG data
(2) indicates text missing or illegible when filed

metry analysis method, and localization of electrical activity
in the brain using inverse EEG computation analysis.
0029 Findings from the aforementioned analyses may
then be statistically compared to the same parameters deter
mined from “eyes open”, “eyes closed”, and “PPT EEG
records taken from an age and gender matched database of
healthy normal individuals. Such statistical analyses may
include, but are not limited to deviations from a standard

normal distribution. Findings of Statistically significant
abnormal deviation, or lack thereof, may then be presented in
a graphical or numerical format for analysis by a competent
health care professional or person of similar expertise.
0030 EEG abnormalities consistent with those observed
in a sample population of fibromyalgia patients may include,
but are not limited to one or more of the following: (1) an
overall reduction in EEG power across all spectra in either of
the “eyes open' or “eyes closed’ conditions; (2) statistically
significant low EEG power levels in frontal or temporal
regions of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or
alpha (8-12 hertz) frequency segments of EEG for the “eyes
closed’ condition; (3) statistically significant low coherence
among the frontal EEG sites for the delta or theta EEG seg
ments in either of the “eyes closed’ or “eyes open condi
tions; (4) statistically significant high relative beta (12.5-25
hertz) absolute power in the parietal region of the brain for
either of the “eyes closed’ or “eyes open conditions. The
magnitude of statistical variation considered statistically
“significant may vary depending on the application. For
example, in research, a difference between a sample and a
population measure generally has to have a p-value of 0.01 or
less for the difference to be considered statistically “signifi

0032. A diagnosis of fibromyalgia may be made when
physical assessment findings that Support a diagnosis of
fibromyalgia are augmented by making a quantitative assess
ment including but not necessarily limited to a statistical
comparison between the subject’s qBEG and a database of
quantitative assessments of either healthy normal individuals
or individuals suffering from a chronic pain related abnormal
brain function condition Such as fibromyalgia. In the pre
ferred embodiment, statistical findings that Support a diagno
sis of fibromyalgia may include, but are not necessarily lim
ited to, (1) an abnormal finding resulting from the TPP test,
preferably a finding of a statistically significant increase in
EEG absolute power, and particularly in the alpha and beta
segments, in the parietal, occipital, and temporal areas of the
brain as compared to the “eyes closed findings without ten
derpoint palpation for the same subject; and preferably (2) an
abnormal finding resulting from the “eyes closed EEG test,
preferably statistically significant low EEG power levels in
frontal or temporal regions of any of the delta, theta or alpha
frequency segments of EEG for the “eyes closed’ condition,
and most preferably with an additional finding of statistically
significant low coherence among the frontal EEG sites for the
delta or theta EEG segments. Alternately, fibromyalgia may
be diagnosed by statistically comparing a Subjects one or
more qBEG parameters to like qEEG parameters obtained
from at least one healthy normal individual; then comparing
the one or more deviations to deviations detected in a sample
population of known fibromyalgia patients.
0033 Clean EEG records from a subject may be math
ematically analyzed for various time domain and frequency
domain parameters of their electrical signals, consistent with
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analysis techniques already described, and then findings from
these mathematical analyses may be statistically compared to
like parameters taken from an age and gender matched data
base of healthy normal individuals or individuals known to
have fibromyalgia. The statistical comparisons may include,
but are not limited to deviations from a standard normal
distribution of like EEG measures associated with members

of a database of healthy normal individuals or individuals
known to have fibromyalgia. The results of those compari
Sons may then be presented in a graphical or numerical format
for analysis by a competent health care professional or person
of similar expertise for the existence of statistically signifi
cant abnormal deviations, or the lack thereof. A finding in
Support of a fibromyalgia diagnosis would be supported if
there is an absence of any significant deviation between mea
sures from a subjects clean EEG and those from a database
comprising individuals known to have fibromyalgia.
0034 Analyses of clean EEG from a subject may be sta
tistically correlated to measures of symptom severity. As
previously described, analysis findings may be mathemati
cally analyzed for various time domain and frequency domain
parameters of electrical signals. A number of measures of the
magnitude of deviation from standard normal distributions of
either healthy normal EEG or known fibromyalgia patient
EEG can be determined. The magnitudes may be presumed to
be related to the severity of the condition and may be statis
tically correlated to such symptom measures that may
include, but are not limited to, tender point pain pressure
thresholds as determined by an algometer, and various other
indices of pain derived from the algometry measures (e.g. the
Sum of all 18 tender point pain tolerance measures, the aver
age of all 18 tender point pain tolerance measures, etc.). Such
analysis has utility in both predicting symptom severity in
individuals with fibromyalgia, and in determining the effect
of therapeutic intervention to corrector manage symptoms of
fibromyalgia.
0035 EEG analyses may also be used for determining the
location of abnormal brain activity and further for determin
ing points for application of neuromodulation.
0036 Treatment may include the application of a nonin
vasive neuromodulation signal in a manner designed to cor
rect abnormalbrain function identified inaccordance with the

aforementioned EEG analyses. Suitable noninvasive neuro
modulation techniques are disclosed in applicant's U.S.
patent application Ser. No. 1 1/490,255 and applicant’s Inter
national Patent Application Ser. No. PCT/US2008/72395,
which are incorporated herein by reference. The noninvasive
neuromodulation signal may comprise those waveforms
designed to minimize tissue impedance. Such as an “ampli
tude modulated pulse width modulated’ (AMPWM) signal.
An AMPWM signal utilizes a high frequency carrier signal
that is amplitude modulated by a low frequency neuromodu
lation signal. The carrier signal is of Sufficiently high fre
quency so as to be less attenuated by the impedance of tissues
due to their capacitive reactance. The frequencies used in the
neuromodulation signal are lower than the frequency of the
carrier signal, and are chosen to provide therapeutic benefit.
By using the neuromodulation signal to amplitude modulate
the carrier signal, and Subsequently applying the combined
signal to tissues, the neuromodulation signal is less attenuated
by the impedance of the tissue permitting greater penetration
of electrical current and field. The carrier signal is further
pulse width modulated in an AMPWM signal to control the
time averaged current, and hence the power of the signal
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delivered to the tissues. An apparatus for generating and
delivering an AMPWM signal includes any number of elec
tric signal generating devices capable of generating and alter
ing the parameter aspects of an AMPWM signal. Various
forms of an AMPWM signal and apparatus for generating an
AMPWM signal are disclosed in the applicant's U.S. appli
cation Ser. No. 1 1/490,255 and applicant’s International
Patent Application Ser. No. PCT/US08/72395. Reports on the
results of a double-blind, placebo-controlled study of the
efficacy of this treatment are summarized below:
0037. Thirty-nine (39) active treatment (AT) fibromy
algia patients and 38 comparable placebo control
patients completed non-invasive neuromodulation treat
ment, applied twice a week for 11 weeks. The placebo
condition (PL) was created by not delivering the non
invasive neuromodulation signal. Both number of tender
point (defined by the American College of Rheumatol
ogy) and total pain score were evaluated at baseline and
end of treatment. Subjects also completed health impact
questionnaires (Fibromyalgia Impact Questionnaire
FIQ, Symptom CheckList-90SCL-90), Beck Depres
sion Inventory BDI. and sleep quality) at baseline and
end of treatment period, and FIQS in long-term follow
up. Primary outcome measures were changes in the
number of tender points (TePs) and level of TeP pain,
secondary measures were changes in the questionnaire
responses.

0.038 Analysis of results showed AT patients improved
in number of positive TePs, mean 17.4 pre-treatment to
9.9 post-treatment (P<0.001). The between group
change was significantly improved (PL -0.2 versus AT
–7.4, P-0.001). Sixty-two percent (62%) of the AT
group no longer met the tender point criteria for FM
classification following treatment. Similarly, the tender
point score (TPS) for the AT group improved from 36.7
to 56.4 (P<0.001) whereas the control group got slightly
worse, 38.9 to 35.8. The between group change was also
significantly improved (PL -3.2 versus AT +19.6, P-0.
001). The total FIQ score in the AT group improved from
65.1 to 46.0 (P<0.001). In other measures, the AT group
reported 61.8% improvement in sleep quality (P<0.
001). Long term follow-up FIQ analysis was done at an
average of 16.8 months since discontinuation of treat
ment (range 12-28 months). There was a continuing long
term improvement over baseline values (P<0.001).
There were no significant side effects.
0039 Mitigation of abnormal activity is accomplished by
generating and applying to the Subject an electrical stimula
tion signal having at least one parameter configured to modu
late at least one abnormal aspect of the subject's EEG, which
corresponds to at least one statistically significant difference
found in the statistical comparison of qEEGs. Such abnormal
aspects of the subject's EEG may include, but are not limited
to, abnormally high or low amplitudes, abnormal amplitudes
in specific frequencies or frequency segments, abnormal
spectral power, abnormal relative power, amplitude asymme
try, and abnormally high or low coherence. The application of
said electrical stimulation signal, preferably an AMPWM
noninvasive neuromodulation signal, may comprise a first
step of choosing neuromodulation signal parameters
intended to correct abnormal brain function identified in

accordance with the aforementioned EEG analyses. These
parameters may include, but are not limited to, a choice of the
carrier signal frequency, neuromodulation signal frequency,
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amplitude, waveform, duty cycle, application times, and
phase. The step of choosing neuromodulation signal param
eters may include identifying a particular signal parameter,
Such as a frequency from a patient's EEG, that is statistically
different than normal, e.g., an EEG frequency that is lower
than normal at a particular location. The chosen neuromodu
lation signal parameters may thus, for example, include a
frequency generally equal to that of the abnormally low mea
Sured EEG frequency. The step of choosing neuromodulation
signal parameters may alternatively or additionally include
identifying an area of the brain where the spectral amplitude
of an EEG frequency measure is found to be statistically
different than normal. This step may further include identi
fying the direction and magnitude of said spectral amplitude
deviation from normal for said statistically different than
normal EEG frequency measure. The identifying step may
yet further include choosing signal parameters that include
frequencies ranging between the frequency of the statistically
different than normal measure (F1) and a frequency that is (a)
within an approximate range of from 20 Hertz greater than F1
to F1 for the case in which the direction of deviation for F1 is

less than normal; or (b) within an approximate range of from
20 Hertz less than F1 to F1 for the case in which the direction

of deviation for F1 is greater than normal. The identifying
step may further include choosing signal amplitudes and
application times that are proportional to the magnitude of
deviation from normal for said statistically different than
normal EEG frequency measure. The identifying step may
further include choosing signal duty cycle so as to provide a
signal that cannot be felt by a person when applied. The
identifying step may further include choosing a signal wave
form that encompasses at least one of the frequencies in the
range of F1 plus or minus 20 Hertz. The identifying step may
also include applying at least two neuromodulation signals to
different areas of the brain, and applying a phase shift
between the at least two signals where the phase shift may
range between Zero and 180 degrees.
0040. The application of a noninvasive neuromodulation
signal may further comprise the step of choosing neuromodu
lation signal application location to provide for application of
neuromodulation to tissues corresponding to one or more of
the spatial location(s) of abnormal brain function identified
by the aforementioned analyses. Signal application may fur
ther include the use of electrodes to create a signal path
between an electrical stimulation signal source Such as an
apparatus for generating an AMPWM signal and a stimulat
ing electrode positioned proximate to brain tissues in at least
one area of abnormal brain activity, either invasively or non
invasively.
0041) Delivery of the neuromodulation signal may be
accomplished by utilizing an electrode set comprising inva
sive stimulating electrodes positioned on or in near proximity
to brain tissues exhibiting abnormal function, i.e., within
approximately 20 mm. The electrode set may further com
prise an invasive ground electrode positioned Such that a
vector path between stimulating electrodes and a ground elec
trode passes through tissues to be stimulated.
0042. Delivery of the neuromodulation signal may be
accomplished by utilizing an electrode set comprising one or
more non-invasive stimulating electrodes adapted to be worn
by a subject such that the stimulating electrodes rest on the
Scalp in proximity to brain tissues exhibiting abnormal func
tion. The electrode set may further comprise a non-invasive
ground electrode adapted to be worn by a subject such that the
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non-invasive ground electrode rests on the scalp in proximity
to brain tissues exhibiting abnormalfunction; positioned Such
that a vector path between non-invasive stimulating elec
trodes and a non-invasive ground electrode passes through or
in near proximity to tissues to be stimulated.
0043. Delivery of the neuromodulation signal may be
accomplished by utilizing an electrode set comprising one or
more non-invasive stimulating electrodes adapted to be worn
by a subject such that the stimulating electrodes rest on the
skin posterior to the cervical vertebrae and in proximity to the
vagus nerve. The electrode set may further comprise a non
invasive ground electrode adapted to be worn by a subject
Such that the non-invasive ground electrode rests on the scalp
in proximity to brain tissues exhibiting abnormal function;
positioned such that a vector path between non-invasive
stimulating electrodes and a non-invasive ground electrode
passes through or in near proximity to tissues to be stimu
lated.

0044) The period of time over which therapeutic interven
tion takes place may comprise repeated application of a neu
romodulation signal for finite duration, with rest time taking
place between applications, and total number of applications
comprising a finite number. The finite duration may be
between one second and 60 minutes; the rest time may be
between one minute and seven days; and the total number of
applications may be between one application and 300 appli
cations. The number of applications may be proportional to
either the extent of abnormal function and/or the time that the

abnormal function has been present
0045. The method of generating described neuromodula
tion signals may include the use of an apparatus such as that
disclosed in the applicant's U.S. patent application Ser. No.
1 1/490.255, which is assigned to the assignee of the present
application and incorporated herein by reference.
0046. The method may include the steps of repeating
quantitative assessments such as EEG testing, TPP testing
and statistical analysis on a subject, as described herein, fol
lowing a period of therapeutic intervention on said Subject.
The method may further comprise statistical comparison of
parameters of the repeated Statistical analysis to like param
eters of the statistical analysis of the subject done before the
previous therapeutic intervention was started. Such compari
son might include, but is not limited to, paired t-testing sta
tistics, correlation analysis of changes in Symptom severity,
and Subsequent comparison to a database of age and gender
matched healthy normal individuals or individuals suffering
from a brain related chronic pain condition Such as fibromy
algia. These comparisons may be used to assess the effective
ness of the therapeutic intervention, in particular noninvasive
neuromodulation, or to determine if an alternate intervention
is indicated in the absence of treatment effect from a current

therapeutic intervention. The comparisons could also be used
to determine if further therapeutic intervention is indicated in
the absence of any abnormal findings. The comparisons may
further be used to modify neuromodulation signal parameters
in accordance with the findings of the repeated quantitative
assessment step.

0047. With specific reference to the TPP test, repeat test
ing may include the application of tender point pressure
using, e.g., an algometer, only to the levels required to cause
a painful response recorded in the same testing performed
before therapeutic intervention.
0048. Further according to the method, EEG data may be
acquired at a first location (e.g. a clinical location) and the
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acquired EEG data transferred via electronic means to
another location (e.g. a central analysis location) for the
herein described analysis and statistical comparisons to be
accomplished. The electronic means of data transfer may
include, but isn't limited to means of data transfer across a

local area network and/or the Internet. Consequently, analysis
and Statistical findings may then be transferred from a central
analysis location to a clinical location, where they may be
used in various ways by a physician or similarly qualified
health care professional for the determination of parameters
of a neuromodulation signal used for therapeutic intervention
and treatment of fibromyalgia.
0049 Further according to the method, EEG data may be
acquired at a first location (e.g. a clinical location) and the
acquired EEG data transferred via electronic means to
another location (e.g. a central analysis location) for a pur
pose such as increasing the size of various databases of indi
viduals known to be suffering from fibromyalgia, individuals
known to be suffering from a chronic pain condition that is not
fibromyalgia, and healthy normal individuals.
0050. Further according to the method, neuromodulation
signal parameters may be determined at a central analysis
location and Subsequently transferred as data via electronic
means to an apparatus at another location (e.g. a clinical
location) provided for delivery of a neuromodulation signal
used for therapeutic intervention and treatment of fibromyal
gia. The electronic means of data transfer may include, but
isn't limited to, means of data transfer across a local area
network and/or the Internet.

0051. The steps of application of the neuromodulation
signal and repeat measurements and analyses of a subjects
EEG may be continued until abnormal brain function, as
determined by, for example, EEG analysis, is modulated and/
or mitigation or resolution of symptoms of the chronic pain
condition (such as fibromyalgia) are achieved.
0052 Alternatively, non-EEG methods of assessing brain
function may be utilized to quantify and locate abnormal
brain function. Such methods include, but are not limited to

positron-emission tomography (PET) scans, magnetic reso
nance imaging (MRI) testing and single photon emission
computed tomography (SPECT) scans.
0053 Alternatively, EEG data may be collected during a
therapeutic intervention that includes application of an elec
trical stimulation signal Such as a neuromodulation signal,
and that EEG data may be analyzed by real-time computa
tional algorithms such as Fast Fourier Transforms (FFT) to
determine various statistics associated with EEG, including
but not limited to spectral amplitudes of frequencies compris
ing said EEG. The statistics may be used to modify param
eters of a neuromodulation signal for the purposes of opti
mizing therapeutic benefit. In a preferred embodiment, EEG
data collected during a therapeutic neuromodulation signal
application is analyzed for spectral components using an FFT
algorithm. A comparison between the frequency of a stimu
lation signal and the highest spectral amplitude of measured
EEG signal is made. If said comparison finds these frequen
cies to be the same, then a corresponding modification to the
neuromodulation signals frequency would be made.
0054 As shown in FIG. 2, the abnormal brain function
diagnostic and treatment apparatus 100 may include a com
puter 101 interfaced to a signal generation and interface mod
ule 121 utilizing any number of methods known in the art such
as the use of a computer interface cable 102. Any power
source 103 known in the art to sufficiently provide power to
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computers and electronic devices may be utilized and exter
nally interfaced with power wires 104. The signal generation
and interface module 121 may include a microcontroller 106
electronically coupled to a signal generator circuit 107, to an
EEG acquisition circuit 108 and to any number of device
interface circuits 109. All external interfaces may utilize con
nectors 105 commonly known in the art. All electrical and
electronic coupling methods may utilize conductors 112
known in the art.

0055. In practice, the computer 101 may be configured to
communicate via interface 102 to the microcontroller 106 for

various purposes including the transfer of AMPWM signal
parameters and the receipt of EEG data. The computer 101
may include a user interface that allows an operator to moni
tor and/or influence operation of the diagnostic and treatment
apparatus 100.
0056. A neuromodulation signal such as an AMPWM sig
nal may be generated in the signal generator circuit 107 and
delivered to a stimulation signal interface 110 that includes
connectors 105. As shown in FIG. 3, the signal generator
circuit 107 may comprise a biopotential amplifier 114 that
measures EEG signals and may be operatively coupled to any
number of filter 115 circuits configured to reduce extraneous
electrical noise in an EEG signal. The biopotential amplifier
114 may be further operatively coupled to an isolation ampli
fier 116 for human subject protection, and to a microcontrol
ler 106 through an analog-to-digital interface 117. In opera
tion, EEG may be acquired through a stimulation signal
interface 110 comprising electrical conductors 5 interfaced at
connectors 105. The acquired EEG may be conducted to a
biopotential amplifier 114, filter circuits 115, isolation ampli
fier 116 and to a microcontroller 106 for use such as, but not

limited to, in software executed by an interfaced computer
101 for generating and delivering an AMPWM signal. The
signal generator circuit 107 may further comprise an isolated
power supply 118 configured to provide circuit power and
provide human Subject protection, a Switching transistor 119
that has base connection to a digital-to-analog interface 121
on a microcontroller 106, and an inductor 120 configured and
positioned to induce an electrical stimulation signal Such as
an AMPWM signal into a conductor 112 leading to a connec
tor 105 in a stimulation signal interface 110. In operation, the
microcontroller 106 may generate a stimulation signal and
conduct that signal via a digital-to-analog interface 121 to the
base of the switching transistor 119. Electrical power from an
isolated power supply 118 may then switched on and off
through the Switching transistor 119 creating an amplified
stimulation signal in accordance with the stimulation signal
waveform generated by the microcontroller 106. The ampli
fied stimulation signal may be further conducted to an induc
tor 120, and further induced into a conductor 112 creating a
therapy stimulation signal in the conductor 112. The therapy
stimulation signal may then be delivered to a human Subject
via the conductor 112 to a stimulation signal interface 110
comprising electrical conductors 5 interfaced at connectors
105. In other words, the neuromodulation signal may be
applied using an apparatus comprising a microcontroller 106
configured to generate signal waveforms and coupled to a
signal generator circuit 107 configured to transform the signal
waveforms into desired AMPWM neuromodulation signals.
The signal generator circuit 107 may comprise circuit ele
ments such as a biopotential amplifier 114 configured to
measure EEG signals, a filter circuit 115 configured to reduce
electrical noise in EEG signals, an isolation amplifier 116
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configured to protect human Subjects, an analog-to-digital
interface 117 configured to convert analog EEG signals to
digital signals, an isolated power Supply 118 configured to
provide circuit power and human Subject protection, a Switch
ing transistor 119 configured to generate an amplified stimu
lation signal by Switching on and off electrical power from the
isolated power Supply in response to stimulation signals
received at a base of the switching transistor from the micro
controller, and an inductor 120 configured to induce an elec
trical stimulation signal into a conductor 112. Additional
forms of an AMPWM signal and apparatus for generating an
AMPWM signal are disclosed in the applicant's U.S. patent
application Ser. No. 1 1/490.255, which is incorporated herein
by reference in its entirety.
0057. As shown in FIG.4, the apparatus 100 may include
a cap 3 configured to be worn on a subjects head in a prede
termined orientation. At least two electrodes 1, 2, which may
be non-invasive type electrodes, may be carried by the cap.
One of the electrodes 1 may be configured to act as a stimu
lating electrode 1 for delivering a neuromodulation signal to
the subject's head 4, and the other of the electrodes 2 may be
configured to act as a ground electrode and to receive neuro
modulation signals transmitted by the signal delivery elec
trode 1. The cap 3 may be of any suitable configuration to
include a skull-cap configuration as shown in the drawings, or
may simply comprise flexible bands. In any case, the cap 3 is
adapted to carry the electrodes 1, 2 and to be worn on the head
4 during mitigation of abnormal brain activity, and, more
particularly, to facilitate non-invasive neuromodulation sig
nal delivery to a subjects brain.
0058 EEG from a subject may be collected through the
EEG acquisition circuit 108, which may include any form of
EEG amplifier instrument known in the art, through an EEG
interface 111 that may include connectors 105. At least one
additional electrode 16 may be carried by the cap 3 and
positioned to sense and transmit EEG signals to the EEG
acquisition circuit 108. Alternatively, a stimulating electrode
1 may also serve as an EEG sensor. In other words, one or
more stimulating electrodes 1 may be coupled to the EEG
acquisition circuit 108 and configured to sense and transmit
EEG signals to the EEG acquisition circuit 108. The cap 3
may also carry electrical conductors 5 that provide signal
paths between an electrical stimulation signal source Such as
the signal generator circuit 107 of the diagnostic and treat
ment apparatus 100 and stimulating electrodes 1 and ground
electrodes 2; and the electrical conductors 5 may also provide
signal paths between an EEG acquisition circuit 108 and
additional electrodes 16, whereby the conductors may elec
trically couple to connectors 105 at a stimulation signal inter
face 110 and an EEG interface 111 of a diagnostic and treat
ment apparatus 100. The stimulating electrodes 1 and ground
electrodes 2 may be permanently or removably affixed into
the cap 3 in cap locations where, when the cap 3 is placed on
a subjects head 4 in a predetermined orientation, the stimu
lating electrodes 1 and ground electrodes 2 are positioned
proximate to respective areas 11 of brain tissues to be stimu
lated, e.g., areas of brain tissue associated with abnormal
brain activity.
0059. The electrodes 1, 2 may be permanently or remov
ably supported in cap locations on the cap 3 so that, when the
cap is worn on a subjects head in a predetermined orienta
tion, a vector path 12 extending between the stimulating
electrode 1 and the ground electrode 2 passes through the
desired area 11 of brain tissues to be stimulated. Further, the
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cap 3 may be sized in various ways to fit or to be adjustable to
a variety of sizes and shapes of human heads 4 and to carry
any number of stimulating electrodes 1 and ground electrodes
2 in cap locations that will cause neuromodulation signals to
pass along vector paths 12 through predetermined locations
of abnormal brain activity 11 in a subject’s brain 10. The
electrodes 1, 2 may Subsequently be removed and placed in
new cap locations that will cause neuromodulation signals to
pass along vector paths 12 through predetermined locations
of abnormal brain activity 11 in a second subject’s brain 10.
0060. The cap 3 may be configured to carry any number of
electrical circuits known in the art for storing information. As
shown in FIG. 5, such circuit may include a radio frequency
identification (RFID) chip 7 incorporated into a cap 3 and
utilized to store information including, but not limited to, the
identification of the subject the cap is intended to be used on,
dates and times of use, parameters of an electrical stimulation
signal to be used in association with the cap and delivery of
non-invasive neuromodulation, a total number of times the

cap has been used and monitoring data associated with qual
ity of use.
0061 The diagnostic and treatment apparatus 100 may
include any number of external devices that may be utilized in
the process of providing assessment, diagnostics, or therapy
and that may be coupled to the device interface circuit 109 and
interfaced through a device interface 113 that may include
connectors 105. For example, the apparatus 100 may include
an RFID reader 14 for establishing electrical connectivity
between the microcontroller 106 and the RFID chip 7through
a device interface 113. The use of an RFID reader 14 and

RFID chip 7 creates a radio frequency pathway 13 that allows
information incorporated into the RFID chip 7 may be
accessed and utilized by software executed by the microcon
troller 106 and/or an interfaced computer 101.
0062. As shown in the embodiment illustrated in FIG. 6, as
an alternative to the use of an RFID chip 7, other suitable
methods known in the art for accessing information stored in
electrical circuits may be used, such as methods that use
direct electrical connections via conductors such as wires 8.

Such methods may include the use of any number of program
mable memory circuits 9 connected via wires 8 to a memory
circuit programmer 15, which may be further interfaced to the
microcontroller 106 and/or the computer 101 through the
device interface 113, such that information incorporated into
the programmable memory circuit 9 may be accessed and
utilized by the microcontroller 106 and/or the computer 101
via, for example, software executed by the computer 101.
0063 Alternatively, neuromodulation may be used as a
method of treatment for fibromyalgia in combination with
treatment of other coexisting physical conditions that may or
may not be associated with fibromyalgia. In addition, or alter
natively, neuromodulation may be used as a method of treat
ment in combination with otherforms of treatment utilized to

affect symptoms of fibromyalgia.
What is claimed is:

1. A method for treating brain-related chronic pain disor
ders, the method including the steps of
assessing the brain function of a Subject Suffering from
chronic pain;
determining a pain-related abnormal brain condition by
determining the presence of brain dysfunction related to
pain;
locating at least one area of abnormal brain activity asso
ciated with the brain dysfunction; and
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mitigating the brain dysfunction by applying an electrical
stimulation signal to tissues corresponding to the at least
one area of abnormal brain activity.
2. The method of claim 1 in which the electrical stimulation

signal comprises waveforms configured to minimize tissue
impedance.
3. The method of claim 2 in which the electrical stimulation

signal comprises an AMPWM signal.
4. The method of claim 1 in which:

at least one of the assessing and locating steps includes
obtaining an electroencephalogram (EEG) of the Sub
ject's electrical brain activity;
the determining step includes obtaining a quantitative
assessment (qEEG) of the subject's EEG and making a
statistical comparison between the subject’s qEEG and a
database of qEEGs of either healthy normal individuals
brain functions or the brain functions of individuals

suffering from the chronic pain-related abnormal brain
function condition; and

the mitigating step includes generating and applying to the
Subject an electrical stimulation signal having at least
one parameter configured to modulate at least one
abnormal aspect of the subject's EEG, which corre
sponds to at least one statistically significant difference
found in the statistical comparison of qEEGs.
5. The method of claim 4 in which the mitigating step
includes testing for EEG lead interface integrity by analyzing
a measured EEG signal.
6. The method of claim 1 in which:

the determining step includes diagnosing fibromyalgia by
making a statistical comparison between the Subjects
qEEG and a database of qBEGs of either normal, healthy
individuals or individuals suffering from fibromyalgia,
and

the mitigating step includes generating and applying to the
Subject a neuromodulation signal.
7. The method of claim 6 in which at least one neuromodu

lation signal parameter to be configured for modulation is
selected from the group of parameters consisting of carrier
signal frequency, neuromodulation signal frequency, ampli
tude, waveform, duty cycle, application times, and phase.
8. The method of claim 6 in which the neuromodulation

signal is applied using an apparatus comprising:
a signal generation and interface module including a
microcontroller configured to generate signal wave
forms and coupled to a signal generator circuit config
ured to transform the signal waveforms into desired
AMPWM neuromodulation signals;
a cap configured to be worn on a Subjects head and carry
ing first and second electrodes in respective cap loca
tions that, when the cap is placed on a Subjects head,
position the electrodes adjacent a predetermined area of
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10. The method of claim 6 in which the neuromodulation

signal is applied repeatedly, alternating with rest periods.
11. The method of claim 6 in which:

at least one of the assessing and locating steps includes
obtaining an electroencephalogram (EEG) of the Sub
ject's electrical brain activity;
the diagnosing step includes obtaining a quantitative
assessment (qEEG) of the subject's EEG and making a
statistical comparison between the subject’s qEEG and a
database of qEEGs of either healthy normal individuals
brain functions or the brain functions of individuals

suffering from the chronic pain-related abnormal brain
function condition; and

the mitigating step includes generating and applying to the
Subject a neuromodulation signal having at least one
parameter configured to modulate at least one abnormal
aspect of the subjects EEG, which corresponds to at
least one statistically significant difference found in the
statistical comparison of qEEGs:
the assessing and quantitative assessment steps are
repeated at least once; and
the neuromodulation signal parameters are modified in
accordance with the findings of the repeated quantitative
assessment step.

12. The method of claim 10 in which repeated applications
of neuromodulation signals are continued until the Subjects
abnormal brain function has been modulated.

13. The method of claim 10 in which repeated applications
of neuromodulation signals are continued until the subjects
symptoms have been mitigated.
14. The method of claim 1 in which at least one of the

assessing and locating steps includes:
collecting EEG, MRI, PET, or SPECT data during electri
cal stimulation signal application;
determining at least one statistic associated with the col
lected EEG, MRI, PET, or SPECT data by analyzing the
collected data using at least one real-time computational
algorithm; and
modifying at least one electrical stimulation signal param
eter in response to the at least one statistic.
15. The method of claim 1 in which:

the diagnosing step includes obtaining a quantitative
assessment of the Subject's brain function; and
identifying any abnormal brain activity by making a statis
tical comparison between the Subject’s quantitative
brain function assessment and a database of quantitative
assessments of either healthy normal individuals’ brain
functions or the brain functions of individuals suffering
from the chronic pain-related abnormal brain function
condition.

electrical conductors that provide signal paths between the
signal generation and interface module and the cap.

16. The method of claim 1 in which the mitigating step
includes mitigating abnormal brain activity by applying a
neuromodulation signal to tissues corresponding to the at
least one area of abnormal brain activity.
17. The method of claim 16 in which the mitigating step

9. The method of claim 6 in which:

includes:

brain tissues to be stimulated; and

EEG data is collected during neuromodulation signal
application;
at least one statistic associated with the collected EEG data

is determined by analyzing the collected EEG data using
at least one real-time computational algorithm; and
at least one electrical stimulation signal parameter is modi
fied in response to the at least one statistic.

applying a neuromodulation signal along a signal path
between an electrical stimulation signal source and a
stimulating electrode; and
positioning the stimulating electrode proximate brain tis
Sues in the at least one area of abnormal brain activity.
18. The method of claim 16 in which the mitigating step
includes:
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applying a neuromodulation signal along a signal path
between an electrical stimulation signal source and a
stimulating electrode; and
positioning the stimulating electrode on the Subject's scalp
proximate brain tissues in the at least one area of abnor
mal brain activity.
19. The method of claim 18 in which the mitigating step
includes positioning a ground electrode such that a vector
path between the stimulating electrode and the ground elec
trode passes proximate tissues in the at least one area of
abnormal brain activity.
20. The method of claim 18 in which the mitigating step
includes positioning a ground electrode such that a vector
path between the stimulating electrode and the ground elec
trode passes through tissues in the at least one area of abnor
mal brain activity.
21. The method of claim 10 in which the step of applying
the electrical stimulation signal repeatedly alternating with
rest periods includes:
repeating the assessing and quantitative assessment steps at
least once following electrical stimulation signal appli
cation; and

reapplying the electrical stimulation signals with signal
parameters modified in accordance with the findings of
the repeated qualitative assessment step.
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